Connor, Clark & Lunn Investment Management Ltd. Rigel Pharmaceuticals Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $21.8 Billion
  • Q1 2024

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Rigel Pharmaceuticals Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 732,563 shares of RIGL stock, worth $6.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
732,563
Previous 589,006 24.37%
Holding current value
$6.17 Million
Previous $854,000 26.93%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024
BUY
$1.12 - $1.57 $160,783 - $225,384
143,557 Added 24.37%
732,563 $1.08 Million
Q4 2023

Feb 09, 2024
SELL
$0.72 - $1.56 $1,888 - $4,091
-2,623 Reduced 0.44%
589,006 $854,000
Q3 2023

Nov 13, 2023
SELL
$1.07 - $1.39 $9,583 - $12,450
-8,957 Reduced 1.49%
591,629 $638,000
Q2 2023

Aug 10, 2023
BUY
$1.12 - $1.82 $19,256 - $31,291
17,193 Added 2.95%
600,586 $774,000
Q1 2023

May 09, 2023
BUY
$1.25 - $2.0 $13,252 - $21,204
10,602 Added 1.85%
583,393 $770,000
Q4 2022

Feb 10, 2023
BUY
$0.67 - $1.5 $383,769 - $859,186
572,791 New
572,791 $859,000
Q4 2017

Feb 09, 2018
SELL
$3.23 - $4.3 $32,745 - $43,593
-10,138 Closed
0 $0
Q3 2017

Nov 14, 2017
SELL
$2.18 - $2.57 $256,771 - $302,707
-117,785 Reduced 92.07%
10,138 $26,000
Q2 2017

Aug 14, 2017
BUY
N/A
127,923
127,923 $349,000

Others Institutions Holding RIGL

# of Institutions
122
Shares Held
110M
Call Options Held
556K
Put Options Held
33.9K
View Full List

About RIGEL PHARMACEUTICALS INC

RIGL Quotes by TradingView
  • Ticker RIGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 172,836,000
  • Market Cap $1.46B
  • Description
  • Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...
More about RIGL
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email